0
Did it work?
No one outside the company knows — Radical Numerics is withholding the patient's clinical course and outcomes, so there is no public evidence yet on whether the treatment worked.
Why it matters: This is the first claimed use of AI-designed viruses in a human, but without outcome data or peer review, it remains an unverified milestone.
- Radical Numerics says it will not disclose the patient's clinical course or outcomes, citing patient privacy, so the treatment's success is unconfirmed.
- In lab tests, the cocktail containing Omnii-1-designed phages eliminated the patient's antibiotic-resistant bacterial isolate in vitro before it was administered.
- The company's technical report is self-published and has not been peer-reviewed; no trial appears on ClinicalTrials.gov.
- Outside scientists caution that lab results don't guarantee clinical success — Harvard's Michael Baym says he would hold judgment until the treatment is finished and others can examine the viruses.
Room for disagreement
- Radical Numerics frames the case as a milestone, but skeptics note the report is self-published, unpeer-reviewed, and lacks outcome data; Uppsala's Brandon Berryhill says lab measurements alone cannot predict how well a phage will control a real infection.
- The New York Times reported company officials said the FDA authorized a trial, while the company's own report describes a narrower physician-led compassionate-use pathway — and the FDA distinguishes expanded access from a clinical trial, with no trial registered on ClinicalTrials.gov.
AI-generated with web search — may be wrong. Check the linked sources.
